Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 11 04:00PM ET
4.94
Dollar change
-0.01
Percentage change
-0.20
%
Index- P/E- EPS (ttm)-1.27 Insider Own15.97% Shs Outstand55.39M Perf Week-4.26%
Market Cap286.24M Forward P/E- EPS next Y-1.16 Insider Trans0.73% Shs Float48.69M Perf Month-17.11%
Income-69.31M PEG- EPS next Q-0.25 Inst Own61.89% Short Float2.31% Perf Quarter-5.36%
Sales0.00M P/S- EPS this Y23.08% Inst Trans-2.77% Short Ratio2.85 Perf Half Y-9.85%
Book/sh2.05 P/B2.41 EPS next Y-13.17% ROA-58.64% Short Interest1.12M Perf Year481.18%
Cash/sh1.87 P/C2.64 EPS next 5Y- ROE-63.88% 52W Range0.76 - 6.19 Perf YTD397.73%
Dividend Est.- P/FCF- EPS past 5Y40.87% ROI-60.30% 52W High-20.14% Beta1.08
Dividend TTM- Quick Ratio13.79 Sales past 5Y0.00% Gross Margin- 52W Low550.00% ATR (14)0.35
Dividend Ex-Date- Current Ratio13.79 EPS Y/Y TTM-15.28% Oper. Margin- RSI (14)43.70 Volatility6.05% 7.36%
Employees59 Debt/Eq0.02 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price13.00
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q21.95% Payout- Rel Volume0.98 Prev Close4.95
Sales Surprise- EPS Surprise33.91% Sales Q/Q- EarningsNov 07 AMC Avg Volume394.56K Price4.94
SMA20-2.90% SMA50-4.42% SMA20021.17% Trades Volume386,275 Change-0.20%
Date Action Analyst Rating Change Price Target Change
Nov-05-24Initiated Wedbush Outperform $12
Aug-27-24Initiated Guggenheim Buy $11
Jul-17-24Initiated BTIG Research Buy $13
Jun-04-24Initiated Craig Hallum Buy $14
Apr-09-24Initiated Maxim Group Buy $8
Aug-02-22Resumed Canaccord Genuity Buy $17
Jun-15-22Initiated Cantor Fitzgerald Overweight $9
Sep-08-21Initiated ROTH Capital Buy $21
May-27-21Initiated Oppenheimer Outperform $25
May-25-21Initiated H.C. Wainwright Buy $21
Dec-05-24 08:00AM
Dec-03-24 08:00AM
Nov-07-24 04:05PM
Nov-05-24 08:00AM
Sep-19-24 04:05PM
07:30AM Loading…
Sep-09-24 07:30AM
Aug-27-24 08:00AM
Aug-05-24 07:30AM
Jul-31-24 08:00AM
Jun-27-24 08:00AM
Jun-24-24 08:00AM
Jun-14-24 07:30AM
Jun-13-24 11:30PM
04:01PM
May-30-24 08:00AM
07:23AM Loading…
May-22-24 07:23AM
06:27AM
May-21-24 04:05PM
May-15-24 10:54PM
04:05PM
Apr-23-24 08:00AM
Mar-20-24 02:33PM
Mar-06-24 07:30AM
Feb-13-24 04:05PM
Jan-24-24 08:00AM
Jan-23-24 08:00AM
Dec-14-23 08:00AM
Dec-13-23 08:00AM
Nov-24-23 11:14AM
Nov-17-23 08:00AM
04:05PM Loading…
Nov-13-23 04:05PM
Oct-17-23 08:00AM
Oct-11-23 08:00AM
Sep-14-23 04:05PM
Sep-06-23 07:00AM
Jun-27-23 04:05PM
Jun-01-23 12:45PM
May-11-23 04:05PM
Mar-23-23 04:50PM
Mar-08-23 07:00AM
Feb-10-23 04:05PM
Dec-15-22 07:00AM
Nov-09-22 04:05PM
Nov-01-22 07:00AM
Oct-20-22 07:00AM
Sep-15-22 04:05PM
Sep-07-22 07:00AM
Aug-15-22 08:36AM
Jun-01-22 07:00AM
May-12-22 04:05PM
May-04-22 04:01PM
09:33AM
May-01-22 11:25PM
02:00PM
Apr-26-22 04:05PM
Mar-29-22 07:00AM
Mar-23-22 07:00AM
Feb-22-22 07:00AM
Feb-09-22 04:05PM
Nov-12-21 04:05PM
Oct-19-21 12:14PM
Oct-13-21 08:10AM
Oct-12-21 04:05PM
Sep-22-21 04:05PM
Sep-15-21 04:56PM
Sep-09-21 04:05PM
Sep-07-21 04:05PM
Aug-10-21 07:00AM
Aug-03-21 07:00AM
Jun-28-21 07:00AM
Jun-24-21 09:01PM
Jun-03-21 05:35AM
May-31-21 10:17AM
May-27-21 07:00AM
May-20-21 07:00AM
May-18-21 07:00AM
May-17-21 04:05PM
07:00AM
May-04-21 08:00AM
Apr-19-21 08:00AM
Mar-22-21 08:00AM
Mar-08-21 08:00AM
Mar-02-21 05:16PM
Feb-10-21 04:05PM
Jan-12-21 08:30AM
Jan-11-21 07:56AM
Dec-28-20 04:05PM
Dec-03-20 08:00AM
Nov-19-20 08:00AM
Nov-05-20 08:00AM
Oct-09-20 08:30AM
Sep-10-20 08:00AM
Jul-27-20 08:00AM
Jun-15-20 08:30AM
May-28-20 08:30AM
Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its clinical assets include Ersodetug, a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism, and RZ402, an oral plasma kallikrein inhibitor and potential therapy for the chronic treatment of diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Evans DaronCFODec 09 '25Buy5.0410,54953,167131,900Dec 10 09:11 AM
Hogenhuis WladimirDirectorSep 24 '24Buy4.704,25920,01741,767Sep 24 05:14 PM
Hogenhuis WladimirDirectorJun 25 '24Buy4.154,81519,98237,508Jun 27 02:00 PM
ROBERTS BRIAN KENNETHChief Medical OfficerJun 14 '24Buy3.914,30016,82854,352Jun 14 12:51 PM
ROBERTS BRIAN KENNETHChief Medical OfficerJun 14 '24Buy3.913,30012,91613,000Jun 14 12:51 PM
Evans DaronCFOJun 14 '24Buy4.0440,000161,56840,000Jun 14 12:06 PM
Evans DaronCFOMay 29 '24Buy3.504511,578121,351May 31 04:05 PM
ROBERTS BRIAN KENNETHChief Medical OfficerMay 23 '24Buy2.697,50020,13850,052May 28 02:56 PM
Evans DaronCFOMay 24 '24Buy3.232,9429,50313,000May 28 02:48 PM
Evans DaronCFOMay 23 '24Buy2.855816510,058May 28 02:48 PM
ROBERTS BRIAN KENNETHChief Medical OfficerMar 28 '24Buy2.555001,2751,076Mar 29 11:08 AM
Evans DaronCFOMar 15 '24Buy1.6920,00033,83020,000Mar 19 09:17 AM
ROBERTS BRIAN KENNETHChief Medical OfficerMar 14 '24Buy1.8810,00018,80010,000Mar 18 11:20 AM
Kim Young-JinDirectorMar 07 '24Buy1.9136,50369,859115,450Mar 14 10:35 AM
ROBERTS BRIAN KENNETHChief Medical OfficerMar 07 '24Buy1.85500925500Mar 11 10:35 AM
Evans DaronCFOMar 08 '24Buy1.9350,00096,345120,900Mar 08 12:37 PM
Elam Nevan CCEOFeb 26 '24Buy1.685,0008,4007,817Feb 28 11:40 AM
ROBERTS BRIAN KENNETHChief Medical OfficerFeb 23 '24Buy1.696,00010,14040,552Feb 27 08:47 AM
ROBERTS BRIAN KENNETHChief Medical OfficerFeb 26 '24Buy1.702,0003,40042,552Feb 27 08:47 AM
ROBERTS BRIAN KENNETHChief Medical OfficerFeb 16 '24Buy1.317,0009,14234,552Feb 21 11:55 AM
Evans DaronCFOFeb 16 '24Buy1.3041,90054,41170,900Feb 20 07:01 AM
Evans DaronCFOFeb 16 '24Buy1.379,00012,3304,500Feb 20 07:01 AM